25 terminated. 25 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Terminated 25 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Cellcept: new trials by email Literature Review of Cellcept trials Research Report on Cellcept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin - Systemic Lupus Erythematosus | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 12 | 2022-11-30 | 2025-09-09 |
| Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Daratumumab - Recurrent Plasma Cell Myeloma | Phase 2 | Terminated | Srinivas Devarakonda | 1 | 2020-12-22 | 2023-09-28 |
| Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide - Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 2 | Terminated | M.D. Anderson Cancer Center | 1 | 2020-08-19 | 2025-06-29 |
| Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML Clofarabine, Fludarabine, Busulfan - Acute Myeloid Leukemia | Phase 2 | Terminated | Milton S. Hershey Medical Center | 2 | 2020-06-03 | 2023-09-14 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 150 | 2017-09-11 | 2026-05-14 |
| Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Cyclophosphamide, Tacrolimus, Mycophenolate mofetil - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Terminated | Loyola University | 5 | 2017-01-18 | 2024-07-10 |
| Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE) Cyclophosphamide, Fludarabine, Tacrolimus - Lupus Erythematosus, Graft-versus-host Disease | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 | 2016-09-13 | 2019-10-02 |
| BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance anti-thymocyte globulin, Fludarabine, Cyclophosphamide - Kidney Transplantation | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 4 | 2014-01-07 | 2018-09-24 |
| A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA) - Delayed Graft Function | Phase 2 / Phase 3 | Terminated | Matthew Cooper | 25 | 2013-06-01 | 2019-04-26 |
| Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies Total-body irradiation, Donor lymphocytes infusion (DLI), Cyclophosphamide - Malignant Neoplasm | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 4 | 2013-05-17 | 2025-05-16 |
| Crohn's Allogeneic Transplant Study Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate - Crohn Disease | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 2 | 2012-07-17 | 2020-02-17 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY) - Hematologic Malignancy, Leukemia | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 4 | 2012-03-01 | 2025-05-04 |
| High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 20 | 2011-11-16 | 2021-07-20 |
| Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers Fludarabine, Busulfan, Cyclophosphamide - Lymphoma, Leukemia | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 15 | 2010-08-01 | 2026-05-27 |
| Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 46 | 2010-05-19 | 2023-01-23 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer rituximab, mycophenolate mofetil, tacrolimus - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Terminated | University of Nebraska | 20 | 2009-12-10 | 2023-09-06 |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab Fludarabine, Cyclophosphamide, Total body irradiation - Lymphoma, B-cell Lymphoma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 135 | 2009-07-01 | 2018-08-27 |
| Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders Cyclophosphamide, Fludarabine, Mycophenolate mofetil - Sickle Cell Disease | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 43 | 2008-06-23 | 2019-04-17 |
| Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation Sirolimus, Mycophenolate mofetil, Bortezomib - Graft-vs-Host Disease | Phase 2 | Terminated | Dana-Farber Cancer Institute | 15 | 2007-10-01 | 2014-10-21 |
| Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation (TLI) - Lymphoma, B-cell, Lymphoma, Non-Hodgkin | Phase 2 | Terminated | Stanford University | 3 | 2006-10-01 | 2018-05-14 |
Showing 20 of 25. Sign in to see all of them.
Leukemia, Myeloid, Acute (7) · Lymphoma, Non-Hodgkin (7) · Hodgkin Disease (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Myelodysplastic Syndromes (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Graft vs Host Disease (4) · Leukemia (4) · Lymphoma (4) · Lymphoma, Large B-Cell, Diffuse (4) · Burkitt Lymphoma (3) · Lymphoma, B-Cell (3) · Lymphoma, Mantle-Cell (3) · Multiple Myeloma (3) · Hematologic Diseases (2)
Fred Hutchinson Cancer Center (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · M.D. Anderson Cancer Center (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · Stanford University (2) · Dana-Farber Cancer Institute (1) · Hoffmann-La Roche (1) · Loyola University (1) · Matthew Cooper (1) · Milton S. Hershey Medical Center (1) · Srinivas Devarakonda (1) · University of Nebraska (1)
United States (25)
Dolores Grosso, DNP, CRNP (2) · Ajay Gopal (1) · Amin Alousi, MD (1) · Corey Cutler, MD (1) · George Georges (1) · Javier Bolanos-Meade, MD (1) · Jeremy S Connors, MD (1) · Joan Merrill, M.D. (1) · Johnnie Orozco (1) · Kanwaldeep Mallhi (1) · Laura Johnston (1) · Lode Swinnen, MD (1) · Masumi Ueda Oshima (1)
PMID 26183076, PMID 30878319, PMID 38283244, PMID 41043099, PMID 41569644
P30CA015704 (5), P01CA015396 (1), P01CA044991 (1), P01CA078902 (1), P01HL122173 (1), P30CA006973 (1), P30CA036727 (1)